Onchilles Pharma key facts
- Operator of a drug discovery and development company intended to build myeloid-focused cancer therapeutics.
- It has raised $35.6M across 1 recorded rounds; the latest was Seed Round ($3.6M) in Jun 2020.
- Notable investors include Polsky Center for Entrepreneurship and Innovation at the University of Chicago, Kennedy Lewis Investment Management, The University of Chicago Office of Investments, InVivium Capital, LYZZ Capital — 7 tracked in total.
- Onchilles Pharma has filed 1 Form D with the SEC, most recently Jul 2020 ($3.6M sold to 10 investors).
- Status: Privately Held (backing).
- ·Watch Onchilles Pharma: the Monday email on marks, rounds and moves
Onchilles Pharma funding rounds
1 roundsHow much has Onchilles Pharma raised?
Onchilles Pharma has raised $35.6 million in total; 1 of its rounds is on record. The largest on record was a $3.6 million seed round in Jun 2020.
Onchilles Pharma has filed 1 Form D with the SEC, most recently in Jul 2020 ($3.6 million sold to 10 investors).
Onchilles Pharma investors
7 investors are on record for Onchilles Pharma, including Polsky Center for Entrepreneurship and Innovation at the University of Chicago, Kennedy Lewis Investment Management, The University of Chicago Office of Investments and InVivium Capital. The seed round in Jun 2020 drew 10 investors.
About Onchilles Pharma
Operator of a drug discovery and development company intended to build myeloid-focused cancer therapeutics. The company leverages novel neutrophil and macrophage biology to develop the next generation of immunotherapies, enabling medical professionals to treat cancer patients efficiently.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2017
- Employees
- 9
- Website
- onchillespharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Onchilles Pharma doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.